|June 30 - Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration
In the current global wave of biotech industry development, Taiwan and Japan are both active participants with strong incentives and robust infrastructure. As the world's third largest market for biomedicine, a mature value chain has been established in Japan with both strong pharmaceutical companies and advanced basic research providers. Taiwan, with strong entrepreneurship, an active capital market, internationalized talent, and a centralized and highly regarded healthcare system, biotechnology is building up to become one of Taiwan's most significant industries. Utilizing the complementary advantages and unlimited collaboration potential between the booming biotech industries of Taiwan and Japan, DCI Partners, a subsidiary of Daiwa Corporate Investment (DCI Group), established the "Daiwa TW-JP Biotech Fund" in 2015. Through this fund, DCI Partners is now dedicated to investing in private companies with advanced projects or platforms. Through these investments, DCI Partners aims to actively add value to the investee and facilitate increased collaboration between Taiwan and Japan.
To energize such collaboration, DCI Group is honored to organize the "Witness the Unlimited Potential of Taiwan-Japan Biotech Collaboration" forum during BioTaiwan 2017, the biggest event of the Taiwan biotech industry calendar. This forum will focus on the following topics:
BioTaiwan 2017 Agenda Register NOW！